Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Wins Genentech, But Will Biotech Employees Remain?

This article was originally published in The Pink Sheet Daily

Executive Summary

With a sweetened bid, the Swiss pharma gains the blessing of Genentech’s special committee, but whether the innovator’s valuable staffers sanction the union is an open question.

You may also be interested in...



California Hangs On To Its Biotech Crown, But Other States Are Luring Some Jobs

Should I stay or should I go? A new survey suggests many top execs think manufacturing and R&D are better off out-of-state.

California Hangs On To Its Biotech Crown, But Other States Are Luring Some Jobs

Should I stay or should I go? A new survey suggests many top execs think manufacturing and R&D are better off out-of-state.

Blinding Them With Science: Genentech Tries To Win Shareholders Over

Genentech's March 2 presentation to analysts and investors - a four hour plus love-in dominated by talk of peptides and pathways - seems to have worked

Related Content

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel